Wall Street analysts forecast that Bristol-Myers Squibb Company (NYSE:BMY) will post sales of $5.15 billion for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Bristol-Myers Squibb’s earnings. The highest sales estimate is $5.19 billion and the lowest is $5.10 billion. Bristol-Myers Squibb reported sales of $4.92 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 4.7%. The company is expected to announce its next quarterly earnings results before the market opens on Thursday, October 26th.
On average, analysts expect that Bristol-Myers Squibb will report full-year sales of $5.15 billion for the current year, with estimates ranging from $20.30 billion to $20.71 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $21.06 billion per share, with estimates ranging from $20.01 billion to $21.53 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the previous year, the company posted $0.69 EPS. The company’s quarterly revenue was up 5.6% compared to the same quarter last year.
Several equities research analysts have weighed in on BMY shares. Jefferies Group LLC reiterated a “buy” rating and issued a $64.00 target price on shares of Bristol-Myers Squibb in a report on Monday, June 5th. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price objective for the company. in a research report on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Finally, Cowen and Company set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, July 10th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $62.66.
Bristol-Myers Squibb (NYSE:BMY) traded up 0.37% during trading on Friday, hitting $62.93. 4,844,305 shares of the stock traded hands. The company has a market capitalization of $103.20 billion, a P/E ratio of 22.98 and a beta of 1.18. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $63.47. The company’s 50 day moving average is $58.94 and its 200 day moving average is $56.02.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Bristol-Myers Squibb by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after acquiring an additional 333,685 shares during the period. BlackRock Inc. grew its position in shares of Bristol-Myers Squibb by 2.4% in the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after acquiring an additional 2,367,864 shares during the period. State Street Corp grew its position in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after acquiring an additional 1,223,457 shares during the period. Dodge & Cox grew its position in shares of Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after acquiring an additional 459,271 shares during the period. Finally, Northern Trust Corp grew its position in shares of Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after acquiring an additional 910,496 shares during the period. 68.88% of the stock is owned by institutional investors.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.